ARVN GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
Arvinas Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC ® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC ® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC ® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.
Did you know?
Holds 16.1x more cash than debt — a strong balance sheet.
Current Price
$10.51
+6.16%Profile
Valuation (TTM)
Market Cap$675.00M
P/E-8.35
EV—
P/B1.56
Shares Out64.22M
P/Sales2.57
Revenue$262.60M
EV/EBITDA—
Arvinas Inc (ARVN) Quality Analysis
ARVN Profitability
Profitability trend analysis coming soon
ARVN Growth
Growth trend analysis coming soon
ARVN Financial Health
Financial health indicators coming soon
ARVN Quality & Fundamental Analysis
Arvinas Inc (ARVN) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. This quality analysis page evaluates Arvinas Inc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Arvinas Inc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of -30.77% and a return on equity (ROE) of -18.62%. Return on assets (ROA) stands at -11.26%.
The debt-to-equity ratio is 0.02, with a current ratio of 4.92. Operating margin is -45.13%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Arvinas Inc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.